Alterations in the innate and adaptive immune system in a real-world cohort of multiple sclerosis patients treated with ocrelizumab

Clin Immunol. 2024 Feb;259:109894. doi: 10.1016/j.clim.2024.109894. Epub 2024 Jan 6.ABSTRACTB cell depletion by the anti-CD20 antibody ocrelizumab is effective in relapsing-remitting (RR) and primary progressive (PP) multiple sclerosis (MS). We investigated immunological changes in peripheral blood of a real-world MS cohort after 6 and 12 months of ocrelizumab. All RRMS and most PPMS patients (15/20) showed treatment response. Ocrelizumab not only reduced CD20+ B cells, but also numbers of CD20+ T cells. Absolute numbers of monocytes, dendritic cells and CD8+ T cells were increased, while CD56hi natural killer cells were reduced after ocrelizumab. The residual B cell population shifted towards transitional and activated, IgA+ switched memory B cells, double negative B cells, and antibody-secreting cells. Delaying the treatment interval by 2-3 months increased mean B cell frequencies and enhanced naive B cell repopulation. Ocrelizumab reduced plasma levels of interleukin(IL)-12p70 and interferon(IFN)-α2. These findings will contribute to understanding ineffective treatment responses, dealing with life-threatening infections and further unravelling MS pathogenesis.PMID:38185268 | DOI:10.1016/j.clim.2024.109894

Source: Clinical Immunology - January 7, 2024 Category: Allergy & Immunology Authors: L Beckers P Baeten V Popescu D Swinnen A Cardilli I Hamad B Van Wijmeersch S J Tavernier M Kleinewietfeld B Broux J Fraussen V Somers Source Type: research